

CNS Research, Inc.
16 Haliburton Road
East Providence, RI 02906

Phone: 1-800-707-6013
Email: axel@cns-research.com
Fax 1-800-847-4332

Axel Julius Epple, MBA

EXPERIENCE

1997 to Present CNS Research, Inc.
Business Manager

Co-founded CNS Research, Inc., a Site Management Organization. Responsibilities include acquisition of new clinical trials, budget negotiations, promotion and supervision of ongoing projects. CNS is currently providing clinical research services to six investigators in three locations:

450 Veterans' Memorial Parkway #11, East Providence, RI 02914
360 Kingstown Rd Unit 102, Narragansett RI 02882
814 Metacom Ave, Bristol, RI 02809

1995 to 1997 Sardelli & Sons Providence, RI
Export Manager

Consulted with 400 employee company to determine export objectives. Developed an export marketing strategy for consumer products in Germany. Organized a trade show and managed the exhibit for two years in Switzerland. Implemented a direct mail program utilizing toll free numbers in Germany. Interviewed and hired a sales representative for the German market.

1991 to 1993 B. A. Ballou & Co., East Providence, RI
Export Consultant

Traveled to Europe signing up importers as non-exclusive distributors. Increased the number of distributors from one to six companies. Developed a cooperative marketing program in German trade magazines.

1989 to 1997 ARISTO Export Management
Vice President Export

Direct operations for EMC (Export Management Company). Managing exports for US domestic companies to Europe. Representing European companies in the United States.

1985 to 1988 Uhren & Uhrgehäuse Fabrik, Germany
Sales Manager

Responsible for the sale of watch components to industry accounts in Europe. Managed the retail sales of finished watches through a representative in West Berlin. Traveled to Australia, Hong Kong, Panama, Costa Rica, South Africa and Singapore.

1979 to 1980 Ebauche Electronique SA, Switzerland
Management Trainee

Worked in customer service for a Swiss watch company. Received technical training in watch quartz movements. Gained practical experience in French language skills.

EDUCATION

09/85 FHW Fachhochschule fuer Wirtschaft
Pforzheim, Baden-Wuerttemberg, Germany
M.B.A - Int'l Business Marketing & Languages

- 01/83 Universidad de Alcala de Henares,
Alcala de Henares, Madrid, Spain
Diploma de Economia y Derecho international
- 06/80 Universite de Neuchatel Neuchatel,
Neuchatel Switzerland
B.A. / B.S. - French Attestation d'Examen
- 01/80 Brown University, Providence, RI, USA
TOEFL Test of English as a Foreign Language

LANGUAGE SKILLS

German: Native speaker, expert level 45 years, currently used
French Expert level 15 years, currently used
Spanish Intermediate level, 10 years, currently not used

COMPUTER SKILLS

WIN 7 Operating Systems user level proficient
MS Office applications expert level user

Clinical Trials Experience

Negotiated budgets and provided regulatory submissions for the following trials:

CL – 758007 Phase III Study of the Efficacy and Safety of Alzhemed in Patients with Mild to Moderate Alzheimer's Disease.

Exelon (rivastigmine)

A Prospective, 26-Week, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) in Patients with Mild to Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept (donepezil) Treatment

GAL-INT-26

Johnson & Johnson PRD, GAL-INT-26, A randomized, double-blind, placebo-controlled trial to evaluate the safety & efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease.

MS Clinical Trials Experience

109MS301: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis

BiogenIdec: 109MS303: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis.

Novartis Pharmaceuticals Protocol No.: CFTY720DUS01
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

Migraine Clinical Trials Experience

AMDC-104-202: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Outpatients with Migraine Headache.

Phase III, "A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine

Premere™ PFO Closure System for the Effect of Septal Closure of Atrial PFO on Events of Migraine with Remere (ESCAPE Migraine) Trial.

Neuropathy Clinical Trials Experience

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of Fidarestat (SNK-860) in Patients with Diabetic Polyneuropathy.

MEM-MD-006" Evaluation of the Safety and Efficacy of Memantine in the Treatment of Chronic Pain in Patients with Diabetic Neuropathy